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We investigated the effect of pharmacologic preconditioning with HDD, LDD and anti-CD163-dex on ischemia/reperfusion injury.
 Liver cell apoptosis and necrosis were analyzed by stereological quantiﬁcation.
 Anti-CD163-dex and high dose dexamethasone reduces the number of apoptotic cells following ischemia/reperfusion injury.
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a b s t r a c t
Aim: The Pringle maneuver is a way to reduce blood loss during liver surgery. However, this may result
in ischemia/reperfusion injury in the development of which Kupffer cells play a central role. Cortico-
steroids are known to have anti-inﬂammatory effects. Our aim was to investigate whether a conjugate of
dexamethasone and antibody against the CD163 macrophage cell surface receptor could reduce
ischemia/reperfusion injury in the rat liver.
Methods: Thirty-six male Wistar rats were used for the experiments. Animals were randomly divided
into four groups of eight receiving anti-CD163-dexamethasone, high dose dexamethasone, low dose
dexamethasone or placebo intravenously 18 h before laparotomy with subsequent 60 min of liver
ischemia. After reperfusion for 24 h the animals had their liver removed. Bloods were drawn 30 min and
24 h post ischemia induction. Liver cell apoptosis and necrosis were analyzed by stereological
quantiﬁcation.
Results: After 24 h' reperfusion, the fraction of cell in non-necrotic tissues exhibiting apoptotic proﬁles
was signiﬁcantly lower in the high dose dexamethasone (p ¼ 0.03) and anti-CD163-dex (p ¼ 0.03) groups
compared with the low dose dexamethasone and placebo groups. There was no difference in necrotic cell
volume between groups. After 30 min of reperfusion, levels of haptoglobin were signiﬁcantly higher in
the anti-CD163-dex and high dose dexamethasone groups. Alanine aminotransferase and alkaline
phosphatase were signiﬁcantly higher in the high dose dexamethasone group compared to controls after
24 h' reperfusion.
Abbreviations: Anti-CD163-dex, anti-CD163-dexamethasone; ALT, alanine aminotransferase; AP, alkaline phosphatase; AST, aspartate transaminase; BR, bilirubin; GGT,
gamma-glutamyl transferase; HDD, high-dose dexamethasone; HE, hematoxylin & eosin; Hp, haptoglobin; IL-1, interleukin 1; IL-6, interleukin 6; IRI, ischemia/reperfusion
injury; LDD, low-dose dexamethasone; MP, methylprednisolone; NVR, necrotic volume ratio; PM, pringles maneuver; ROS, reactive oxygen species; SURS, systematic,
uniform, random sampling; TNF-a, tumor necrosis factor a.
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Conclusions: We show that pharmacological preconditioning with anti-CD163-dex and high dose
dexamethasone reduces the number of apoptotic cells following ischemia/reperfusion injury.
© 2015 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Limited. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
The level of intraoperative blood loss and the transfusion
requirement are factors known to be associated with the degree of
morbidity and mortality following liver resection [1,2]. Moreover,
these factors are important determinants of the morbidity, mor-
tality and other postoperative complications and the risk of tumor
recurrence [3e9]. Several surgical procedures have been used
during liver resection in an attempt to reduce excessive perioper-
ative bleeding [10]. The most common is Pringle's maneuver, using
inﬂow occlusion by portal triad clamping [11,12]. Lack of oxygen in
the tissue leads to cell damage [13]. This can lead to important
clinical problems including liver dysfunction and liver failure [14].
Ischemia/reperfusion injury (IRI) in the liver results from direct
cellular damage caused by hypoxia and by the associated inﬂam-
matory tissue response, that results in further tissue damage and
dysfunction [15,16]. The ischemic insult results in metabolic dis-
turbances, caused by lack of oxygen, ATP-depletion and glycogen
consumption [17].
An excessive inﬂammatory response during reperfusion plays
an essential role determining the degree of IRI [14]. IRI occurs in
two distinct phases after reperfusion, an early phasewithin the ﬁrst
2 h and a later phase after 6e48 h [18]. In the early phase, reactive
oxygen species (ROS) mainly produced and released from Kupffer
cells aggravate the ischemic injuries [19,20]. In addition, an
increased production of cytokines and chemokines can be detected.
Signaling from ROS, cytokines and chemokines, recruits neutrophil
granulocytes to the hepatic sinusoids, resulting in both local and
systemic inﬂammation [21,22]. Late phase IRI is dominated by
neutrophil inﬁltration, microcirculatory disturbance, and further
damage to the liver [23e25].
Surgical intervention, pharmacological agents and gene therapy
have been investigated as preventative strategies against IRI [26].
Pharmacological studies based on the pathophysiology of IRI have
focused on the use of corticosteroids and antioxidants. Steroids
induce an anti-inﬂammatory effect by providing negative feedback
on immunological stimulation, stabilizing cell membrane integrity
by inhibition of lysosome peroxidation and through regulation of
gene expression pathways [27,28]. Corticosteroids seem to have a
positive impact on the extent of IRI in the liver through an anti-
apoptotic effect [29e33].
A possible pharmacological method to reduce IRI could be a
newly developed antibody drug conjugate (ADC) targeting dexa-
methasone to the receptor CD163 expressed on the surface mac-
rophages and monocytes, anti-CD163-dexamethasone [34e36].
The primary function of CD163 is as a scavenger receptor for the
hemoglobin-haptoglobin (HbeHp) complex formed after the lysis
of red blood cells [37]. Kupffer cells are liver-resident macrophages
that contribute to activation of the immune system by releasing
cytokines such as tumor necrosis factor-alpha (TNF-a) and inter-
leukin 1 and 6 (IL-1 and IL-6) and by the production of ROS [38].
Targeting the CD163 receptor in macrophages highly increases the
anti-inﬂammatory potency of dexamethasone. This has been tested
in a rat and porcine model of inﬂammation after administration of
lipopolysaccharides [34,36]. In these studies anti-CD163-dex at low
dose was comparable to the anti-inﬂammatory effect of high dose
free dexamethasone.
Given that Kupffer cell activation may result in inappropriate
immune system up-regulation crucial to the pathogenesis of IRI, we
hypothesized that anti-CD163-dex at a lower dose than free dexa-
methasone, might protect the liver from ischemic damage, thus
preventing some of the well-known adverse effects of high dose
glucocorticoids. We investigated this in the rat liver.
2. Methods
2.1. Experimental design
All experimental protocols used in this study were approved by
the Danish Animal Experiments Inspectorate according to license
number 2009/561-1644 and followed the rules of the “Guide for
the Care and use of Laboratory Animals” published by the National
Institutes of Health. In the experiment, we used 36maleWistar rats
(Taconic, Eiby, Denmark) with an average weight of 225 g (range
195 ge301 g). The rats were housed in standard animal cages in an
environmental- and temperature-controlled facility, at 23 C and
with a 12-h lightedark cycle. They were given free access to water
and standard food (Altrombin).
Anesthesia was achieved using a mixture of oxygen (2.0 l/min-
ute) and nitrous oxide (0.5 l/minute) containing 4.5% sevoﬂorane
(forene; Abbott Laboratories, UK), blown through an induction
chamber. During tail vein injection and surgery, anesthesia was
maintained with 3% sevoﬂorane in the same mixture of oxygen and
nitrous oxide, administrated through a mask covering the nose of
the rat.
The animals were randomly divided into four groups receiving,
respectively, anti-CD163-dex, high dose dexamethasone (HDD),
low dose dexamethasone (LDD) or PBS intravenous through the tail
vein 16e18 h before liver ischemia. During surgery, the rat was in a
supine position on a temperature-controlled heated pad to main-
tain the core temperature at 37 C. A transverse abdominal incision
was made right under the rib cage. Under a dissecting microscope,
all the hepatic ligaments were resected to achieve abruption of the
collateral blood supply. In addition, the hepatoduodenal ligament
was identiﬁed. A partial hepatic ischemia model was used to pre-
vent mesenteric congestion by allowing blood ﬂow through the
right liver lobe [39].
Portal triad clamping was performed with a micro vascular
clamp after the bifurcature of the right lobe, interrupting the portal
triad ﬂow to the left and median lobes. Discoloration of the lobes
was used as a positive marker indicating hepatic ischemia. The
abdomen was temporarily closed and the respiratory rate was
measured every 10th minute to avoid major loss of ﬂuid and bra-
dypnea. As analgesics, the animals were given a subcutaneous
injected of carprofen 5 mg/kg (Rimadyl; Pﬁzer Animal Health,
Exton, USA) and given intravenous isotonic saline 1 ml. After
30 min of ischemia, a blood sample was collected through the
lateral tail vein to monitor the acid-base status and blood lactate
concentration.
After 60 min of ischemia, the clamp was removed and the blood
ﬂowwas re-established to themedian and left lobes, veriﬁed by the
return of the normal reddish color of the liver. The abdomen was
closed in two layers, the fascia-layer with continuous suture and
the skin-layer with single knots. After 30 min of reperfusion, a
blood sample was collected. No antibiotics were administrated
during the study period.
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After 24 h of reperfusion the animals were re-anesthetized as
described above. The abdomen and thoracic cavity were opened,
and cardiac cannulation was performed to collect blood. Subse-
quently, the animals were euthanized by an intra cardiac injection
of 1 ml pentobarbital 400 mg/ml. To ensure rapid ﬁxation of the
liver, the animal was perfused with phosphate-buffered 4% form-
aldehyde for 10 min through a cardiac cannula. The left portion of
the median lobe was then resected and preserved in the same
ﬁxative for an additional 24 h, after which the lobe was embedded
in parafﬁn.
2.2. ADC synthesis
Anti-CD163-dexamethasone (AD) was produced by conjugating
dexamethasone hemisuccinate-NHS to primary amino groups of
the rat CD163 antibody Ed-2 (ABD Serotec, Düsseldorf, Germany) as
described [34].
Dexamethasone phosphate (SigmaeAldrich, Broendby,
Denmark) dissolved in PBS and PBS-buffer (Invitrogen, Taastrup,
Denmark) was ﬁltered and stored as AD, the study was conducted
blinded [34].
2.3. Stereological sampling
The formaldehyde-ﬁxed left median lobe was cut into 2 mm
thick parallel slabs using a tissue slicer. All slabs were placed hor-
izontally with the same side down in a cage before parafﬁn
embedding allowing correct estimation [40]. A 2 mm section was
cut from each parafﬁn embedded block, creating a set of systematic,
uniform, random sampling (SURS) sections for analysis.
2.4. Immunohistochemistry
Apoptotic cells were identiﬁed by immunohistochemical stain-
ing for caspase 3. This cytosolic molecule is an effector protein,
which causes DNA fragmentation and cell death [41]. Immunohis-
tochemical staining was performed on 2.5 mm parafﬁn slides using
a Benchmark XT automatic stainer (Ventana Medical Systems,
Roche Group, AZ, USA). The primary antibody used in this study
was Asp175 (clone5A1E, 1:80 dilution; Cell Signaling Technology,
Glostrup, Denmark) against the activated form of caspase 3. Bound
antibody was detected using the UltraView DAB detection kit
(DAKO, Glostrup, Denmark). Sections were counterstained with
hematoxoxylin.
2.5. Stereological quantiﬁcation of IRI
All sections were blinded to the investigator and analyzed using
a microscope (Olympus BX-50) modiﬁed for stereology, with a
motorized stage (Prior H138 with controller H29, Cambridge, UK)
and a digital camera (Olympus camera DP72) connected to a PC
with newCAST 3.6.5.0 software (Visiopharm, Hørsholm, Denmark.)
The same investigator analyzed all sections. Intra-observer variance
of stereological datawas tested by re-evaluating multiple randomly
chosen livers as described below.
2.6. Volume estimation
Volumes were estimated in hematoxylin and eosin (H&E)-
stained SURS sections by the Cavalieri method [42]. A point grid
was placed randomly over the H&E section using the software, and
the areas of the entire section and of the necrotic tissue were
estimated, as described [43]. To estimate the volume the following
formula was used:
V ¼ t$a
p
$
Xn
t¼1
Pi (1)
t was the distance between each sampled section
(2 mm ¼ 2000 mm); (a/p) the area covered by each test point; S Pi
was the number of points counted.
The necrotic volume ratio (NVR) was analyzed for each liver
sample. NVR was calculated as:
NVR ¼ Vnecrotic
Vtotal
$100% (2)
Results were adjusted for volume shrinkage as described [43].
2.7. Caspase 3 quantitation
Two-dimensional quantitation of caspase 3-positive cell proﬁles
was performed on SURS sections from each animal as described
[42]. Caspase 3-positive cell proﬁles were estimated by counting
the number of positive cells within an unbiased counting frame. An
average of 150 randomly selected, non-overlapping ﬁelds of view,
were analyzed in each animal. The fraction of caspase 3-positive
cell proﬁles (QA) was calculated using the following formula:
QAviable ¼
P
QP
A
¼
P
QðCasp3Þ
a

mm2

$
P
P$f viable
;
f viable ¼ 1 aNecrotic
aTotal
(3)
in which Q is the number of caspase 3-positive cell proﬁles; a is the
area of the counting frame; and P is the number of counting frames
evaluated; f viable is the fraction of non-necrotic liver tissue used to
correct the reference area. The counting rules used are described in
Fig. 1b.
2.8. Liver parameters
Blood samples obtained after 30 min of reperfusion and from
the cardiac cannulation at 24 h of reperfusion were processed and
stored at 80 C until analysis. Alanine aminotransferase (ALT),
alkaline phosphatase (AP), bilirubin (BR), gamma-glutamyl trans-
ferase (GGT) and haptoglobin (HP) were measured using Roche
Hitachi Cobas 6000 (Roche diagnostics, Mannheim, Germany).
2.9. Inﬂammatory mediators
Plasma IL-1, IL-6 and TNFweremeasured using a speciﬁc rat IL-1
(eBioscience San Diego, CA, USA), IL-6 (RayBiotech, Norcross, GA,
USA), and TNF immunoassays (Invitrogen, Carlsbad, CA, USA). Rat
acute phase proteina-2-macroglobulin was measured using a spe-
ciﬁc ELISA kit (Immunology Consultants Laboratory, Portland, OR,
USA). All of the assays used in this study have previously been
validated for use in rats and were performed as described by
manufacturer's instructions.
2.10. Statistical analysis
Statistical analyses were performed using SPSS 19 (SPSS Inc.,
Chicago, Illinois, USA). All data are expressed as mean (CI). Data
were tested for normal distribution and analyzed by ANOVA. For
comparison of the two groups, normal distributed data were tested
with Student's t-test. Nonparametric data were tested using Krus-
kaleWallis test, followed by the Wilcoxon ManneWhitney Rank
sum test. P-values <0.05 were considered signiﬁcant.
The reproducibility of the stereological data was tested by re-
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evaluation of all sections from respectively 11 and 8 randomly
chosen livers from the two analyses. Data from the ﬁrst (A1) and
the second evaluations (A2) were compared using Wilcoxon Man-
neWhitney Rank sum test. The variability between analysis was
assessed by difference-average as described by Bland and Altman
plot [44].
3. Results
Four animals were excluded because of insufﬁcient clamping
of the blood supply to the liver evaluated by ALT values of less
than 3000 U/L. One animal was excluded due to portal vein
thrombosis.
3.1. Stereology
3.1.1. Apoptosis
After 24 h of reperfusion, the fraction of apoptotic cell proﬁles in
the non-necrotic tissue were 530 cell proﬁles/mm2 (240e821) in
the control group, 219 cell proﬁles/mm2 (83e354) in the anti-
CD163-dex group, 188 cell proﬁles/mm2 (158e218) in the HDD
group, and 235 cell proﬁles/mm2 (129e362) in the LDD group.
Apoptosis was signiﬁcantly lower in the HDD (p ¼ 0.03) and the
anti-CD163-dex (p ¼ 0.05) groups compared with the control
group. The mean number of apoptotic cell proﬁles was lower in the
LDD group (p ¼ 0.06) compared with the control group, but the
difference was not statistically signiﬁcant (Fig. 1).
3.1.2. Necrotic volume and volume ratio (NVR)
After 24 h of reperfusion, the average Vnecrotic was 600
(505e827) in the control group, 498 (161e801) in the anti-CD163-
dex group, 626 (438e832) in the HDD group, and 625 (282e1247)
in the LDD group.
The average Vtotal was 970 (768e1205) in the control group,
991 (853e1146) in the anti-CD163-dex group, 1021 (886e1328) in
the HDD group, and 1087 (814e1745) in the LDD group.
After 24 h of reperfusion, the average NVR could thus be
calculated to 63% (55e71) in the control group, 51% (33e68) in the
anti-CD163-dex group, 62% (52e71) in the HDD group, and 56%
(45e68) in the LDD group. We found no signiﬁcant differences
between the groups (Fig. 2).
3.2. Biochemistry
3.2.1. Liver parameters
As illustrated in Table 1, the post ischemic rise of ALT was
signiﬁcantly higher in the HDD group compared with the control
group after 24 h of reperfusion. However, when testing for multiple
groups (ANOVA) there was no signiﬁcant difference between
groups. After 30 min of reperfusion, we found no difference in ALT
between groups. After 24 h of reperfusion, the mean AP level was
signiﬁcantly higher in the HDD group compared with the control
group, and themean level of HPwas signiﬁcantly higher in the anti-
CD163-dex and HDD groups (Table 1).
Fig. 1. Quantiﬁcation of caspase 3 positive cell proﬁles. a) Box plot of apoptotic cell proﬁles/mm2 liver after 1 h of liver ischemia and 24 h of reperfusion. Horizontal markers indicate
median values of the groups. Apoptosis was signiﬁcantly lower in the HDD (p ¼ 0.026) and the anti-CD163-dex (p ¼ 0.047) groups compared with the control group. b) A typical
study section. Cell proﬁles were counted if they stained positive for caspase 3, if the nucleus of the cell was visible and if the cell proﬁle was inside the counting, touched the green
inclusion lines and did not touch the red exclusion lines. Cell proﬁles counted are marked with a black arrow. (For interpretation of the references to colour in this ﬁgure legend, the
reader is referred to the web version of this article.)
Fig. 2. Quantiﬁcation of necrotic areas. a) Box plot of liver damage after 1 h of liver ischemia and 24 h of reperfusion. Horizontal markers indicate median values of the groups. There
were no signiﬁcant differences in the NVR between the groups. b) An example of a H&E stained study section. Areas of necrosis to be counted are marked with a black arrow.
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3.2.2. Inﬂammatory markers
As shown in Table 2, we found no difference in the post-
ischemic rise in IL-1. The average level of a-2-macroglobulin was
lower in the anti-CD163-dex group compared with the control
group, but this was not signiﬁcant (p ¼ 0.063). After 30 min of
reperfusion, levels of TNF-a and IL-6 were close to the detection
limit in all groups (Table 2).
4. Discussion
We investigated the effect of pharmacologic conditioning with
HDD, LDD and anti-CD163-dex on IRI. We show that conditioning
with anti-CD163-dex and HDD signiﬁcantly decreased the number
of apoptotic cell proﬁles after 24 h of reperfusion, compared with
controls, but was without effect in relation to the amount of ne-
crosis. Our results suggest that both HDD and anti-CD163-dex, at a
50 times lower net dexamethasone dose, protected the rat liver
against IRI, as shown by a reduction in apoptotsis. That HDD pro-
tected against IRI is in agreement with studies by Glanemann et al.
and Saidi et al. who showed that rats pre-treated with systemic
methylprednisolone (MP) 2 min before hepatic ischemia had fewer
apoptotic cells than controls [29,33]. However, the present study is
the ﬁrst to show a reduction in the apoptotic cell count after
administration of macrophage-targeted corticosteroids. Since the
majority of resident macrophages are found in the liver as Kupffer
cells, the greater part of anti-CD163-dex activity is likely to be
directed against these [45]. Thus, we can speculate that cortico-
steroids administered as anti-CD163-dex might have the same
beneﬁcial effects on apoptosis after IRI in the liver as systemic
corticosteroids, but without their side effects [46].
We found no signiﬁcant differences with regard to the amount
of necrosis when comparing anti-CD163-dex, HDD, LDD and
control groups. This is in contrast to Wang et al. [30], who found a
reduction in cell damage after IRI when conditioning with pred-
nisolone, 30 min before 60 min of partial hepatic ischemia. How-
ever, these authors assessed both necrotic and apoptotic cells in
their histological studies, using a semi-quantitative method with
several pitfalls, as discussed later. In contrast, Seleri et al. found that
IRI was aggravated in rats when conditioning with intravenous
corticosteroids 1 h before 60 min of partial hepatic ischemia [47].
Again, liver cell damage was assessed in this paper by semi-
quantitative methods, which might explain some of the discrep-
ancies compared with our study.
ALT and aspartate transaminase (AST) have been used as
biochemical markers of liver cell damage in many studies [29,47].
We found no differences in ALT levels after 30 min of reperfusion
between groups. However, after 24 h of reperfusion, ALT levels
were signiﬁcantly higher in the HHD group compared with the
control group. We did not show any differences with regard to
necrosis between groups, and in addition there were fewer
apoptotic cells in the HDD group. This apparent paradox can most
likely be explained by side effects of systemic corticosteroids in
high doses on the liver as demonstrated by Sileri P et al. [45]. AP
was signiﬁcantly higher in the HDD group compared with the
control group after 24 h. This might of course be a coincidence.
Alternatively, it might be explained by a possible damaging effect of
corticosteroids in high systemic doses on the biliary epithelium,
similar to the one demonstrated by Seleri et al. on hepatocytes. We
cannot decide this for certain, since we did not separately investi-
gate the degree of necrosis or apoptosis in the biliary epithelium.
HP is produced by hepatocytes and is an acute phase protein
elevated in inﬂammatory conditions [48]. HP levels after 30 min of
reperfusion were signiﬁcantly higher in the anti-CD163-dex and
HDD groups compared with the control group. No difference was
Table 1
The table shows an average of the liver parameters measured with conﬁdence intervals.
Control (n ¼ 10) Anti-CD163-dex (n ¼ 9) HDD (n ¼ 8) LDD (n ¼ 8)
ALT [U/l] (30 min) Mean 1853 1730 2258 2496
95% conﬁdence interval for mean (1438e2268) (1259e2201) (1703e2812) (1584e3409)
ALT [U/l] (24 h) Mean (103) 8.96 7.90 12.2* 9.2
95% conﬁdence interval for mean (103) (6.63e11.3) (4.40e11.4) (10.1e14.2) (5.60e12.8)
AP [U/l] (30 min) Mean 218 251 287 268
95% conﬁdence interval for mean (196e239) (213e288) (212e362) (186e351)
AP [U/l] (24 h) Mean 376 393 577* 366
95% conﬁdence interval for mean (315e437) (300e487) (442-711 (300e432)
BR [mmol/l] (30 min) Mean 1.63 1.26 1.49 1.56
95% conﬁdence interval for mean (1.28e1.98) (0.91e1.61) (0.91e2.06) (1.09e2.04)
BR [mmol/l] (24 h) Mean 6.69 5.19 6.24 5.76
95% conﬁdence interval for mean (3.58e9.80) (2.862e7.516) (4.26e8.21) (3.22e8.31)
GGT [U/l] (30 min) Mean 1.12 0.52 0.85 0.61
95% conﬁdence interval for mean (0.21e2.03) (0.07e0.98) (0.13e1.83) (0.19e1.04)
GGT [U/l] (24 h) Mean 8.89 5.90 7.85 5.45
95% conﬁdence interval for mean (5.05e12.73) (2.59e9.21) (6.15e9.55) (3.31e7.59)
HP [g/l] (30 min) Mean 0.111 0.158* 0.334* 0.139
95% conﬁdence interval for mean (0.09e0.13) (0.12e0.20) (0.299e0.368) (0.111e0.167)
HP [g/l] (24 h) Mean 0.161 0.244 0.218 0.204
95% conﬁdence interval for mean (0.067e0.256) (0.132e0.356) (0.107e0.329) (0.106e0.303)
* indicates a signiﬁcant difference compared with the control group (P < 0.05).
Table 2
Interleukin-1 and a-2-macroglobulin: Averages are shown for measurements of IL-1 after 30 min of reperfusion and a-2-macroglobulin after 24 h of reperfusion with con-
ﬁdence intervals. There were no signiﬁcant differences compared with the control group.
Control (n ¼ 10) Anti-CD163-dex (n ¼ 9) HDD (n ¼ 8) LDD (n ¼ 8)
IL-1 [pg/mL] (30 min) Mean 670 898 761 923
95% conﬁdence interval for mean (252e1089) (485e1310) (68e1590) (320e923)
a-2-macroglobulin [mg/ml] (24 h) Mean 1.17 0.81 1.25 1.05
95% conﬁdence interval for mean (0.87e1.48) (0.53e1.09 (0.65e1.84) (0.50e1.60)
L.N.O. Møller et al. / Annals of Medicine and Surgery 4 (2015) 331e337 335
found after 24 h. We did not investigate the amount of inﬂamma-
tion in these experiments and, therefore cannot decide on this
matter. IRI is known to initiate a strong inﬂammatory response,
while in contrast corticosteroids have anti-inﬂammatory properties
[27,28]. However, corticosteroids are also known to increase HP
levels, which might explain this apparent paradox [49].
Kupffer cells produce cytokines, important mediators of the
inﬂammatory response [21,50,51]. We measured cytokines after
30 min. Il-6 and TNF-a were close to the detection limit and there
were no differences in IL-1 between groups. Other studies have
shown a fall in TNF-a levels when preconditioning with predniso-
lone 2 h after reperfusion [31], and a decrease in IL-6 3 h after
reperfusion when preconditioning with MP [33]. One possible
explanation for not detecting higher levels of IL-6 and TNF-a in our
analysis could be that samples were taken early in the inﬂamma-
tory response, i.e. after 30 min.
The exact mechanism of corticoid action on hepatic IRI is un-
known. Steroids in general induce an anti-inﬂammatory effect by
providing negative feedback on immunological stimulation, stabi-
lizing cell membrane integrity by inhibition of lysosome peroxi-
dation and through regulation of gene expression pathways [27,28].
Figuaro at al. were the ﬁrst to suggest that corticosteroid had a
protective effect on IRI in their study from 1975 [52]. They sug-
gested that this protective mechanism might be mediated by cell
membrane protection, either through stabilization of the lysosomal
membrane or by the inhibition of circulating toxic substances
excreted from the liver during ischemia [52]. In the kidneys,
dexamethasone has been shown to up-regulate Bcl-xL, down-
regulate ischemia-induced Bax, and inhibit activation of caspase-
9 and caspase-3, thereby reducing both apoptosis and necrosis.
Dexamethasone has also been shown to decrease the number of
inﬁltrating neutrophils and lower ICAM-1 [53]. However, Wang
et al. suggested that prednisolone appeared to reduce IRI in the
liver by suppressing cytokine release [31] and this might be the
mechanism by which anti-CD163-dex acts in the present study.
Although we could not detect any major rise in cytokines in the
present study at the time of blood sampling, it is likely that this may
be one way by which corticosteroids protect against IRI in the liver.
Clinical studies have shown a beneﬁcial effect of systemic
corticosteroid conditioning before liver surgery [32]. Moreover,
Kotsch et al. [54] showed that MP therapy improved outcome after
deceased donor liver transplantation, reducing inﬂammation in the
donor organ. In liver transplantation, the degree of apoptosis is an
important marker of outcome [55,56]. An anti-apoptotic effect of
treatment with anti-CD163-dex might also improve the outcome in
liver transplantation, opening the way for further therapeutic op-
portunities. Thus, if the severity of IRI can be substantially reduced,
it might be possible to split the donor liver between more
recipients.
In our study, rats were treated with a single dose of anti-CD163-
dex, resulting in a reduction in the number of apoptotic cells. It is
possible, that administering several doses of the conjugate before
liver ischemia could enhance this protective effect, as well as timing
of treatment could perhaps be optimized. One could also speculate
that anti-CD163-dex might be a potential treatment of autoim-
mune liver disorders including primary biliary cirrhosis, autoim-
mune hepatitis, primary sclerosing cholangitis and IgG4-related
liver diseases. In this way one might avoid many of the complica-
tions seen after long-term high-dose corticosteroid therapy. These
considerations need further research.
A major strength of our study was that we used stereological
quantiﬁcation in a blinded and randomized fashion. This is in
marked contrast to previous studies that have used a variety of
semi-quantitative methods to assess IRI. Moreover, an intra-
observer analysis found no signiﬁcant differences in the study
results. In addition, our study was limited by lack of data con-
cerning the inﬂammatory markers due to timing of blood sampling.
However, with the experimental model used, it was not possible to
obtain more than one adequate blood sample before euthanisation.
In conclusion, our study shows that pharmacological condi-
tioning with anti-CD163-dex and HDD reduces the number of
apoptotic cells following IRI compared with controls. We found no
differences with regard to the degree of necrosis. Our ﬁndings do
not allow us to decide whether or not the anti-CD163-dex effect on
IRI was caused by inhibition of the inﬂammatory response.
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